[go: up one dir, main page]

BR9916881A - Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas - Google Patents

Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas

Info

Publication number
BR9916881A
BR9916881A BR9916881-2A BR9916881A BR9916881A BR 9916881 A BR9916881 A BR 9916881A BR 9916881 A BR9916881 A BR 9916881A BR 9916881 A BR9916881 A BR 9916881A
Authority
BR
Brazil
Prior art keywords
ovarian cancer
biodegradable
methods
compositions
poly
Prior art date
Application number
BR9916881-2A
Other languages
English (en)
Inventor
Wenbin Dang
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of BR9916881A publication Critical patent/BR9916881A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA TRATAMENTO DO CâNCER OVARIANO, COMPOSIçõES DE POLI(FOSFOéSTER) E ARTIGOS BIODEGRADáVEIS DAS MESMAS". São descritas composições poliméricas biodegradáveis adequadas para administração intraperitoneal, para tratamento de um indivíduo mamífero com câncer ovariano. A composição compreende: (a) pelo menos um agente antineoplásico e (b) um polímero de fosfoéster biodegradável onde a composição polimérica propicia liberação prolongada do agente antineoplásico ao peritónio do indivíduo; onde a composição polimérica aumenta a taxa de sobrevivência média cancerígena em pelo menos cerca de 10%, se comparado com a taxa de sobrevivência média obtida mediante administração de uma composição compreendendo a mesma dosagem do agente antineoplásico sem o polímero biodegradável. São também descritos artigos sólidos e métodos para tratamento de câncer ovariano.
BR9916881-2A 1999-01-11 1999-12-23 Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas BR9916881A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/227,852 US6350464B1 (en) 1999-01-11 1999-01-11 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
PCT/US1999/030814 WO2000041678A1 (en) 1999-01-11 1999-12-23 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same

Publications (1)

Publication Number Publication Date
BR9916881A true BR9916881A (pt) 2002-05-07

Family

ID=22854735

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916881-2A BR9916881A (pt) 1999-01-11 1999-12-23 Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas

Country Status (20)

Country Link
US (4) US6350464B1 (pt)
EP (1) EP1140028B1 (pt)
JP (1) JP2002534456A (pt)
KR (1) KR20010101472A (pt)
CN (1) CN1337878A (pt)
AT (1) ATE310506T1 (pt)
AU (1) AU779182B2 (pt)
BR (1) BR9916881A (pt)
CA (1) CA2359109C (pt)
CZ (1) CZ20012416A3 (pt)
DE (1) DE69928567T2 (pt)
HU (1) HUP0202670A3 (pt)
IL (2) IL145087A0 (pt)
IN (1) IN2001CH01053A (pt)
MX (1) MX236541B (pt)
NO (1) NO20013402L (pt)
RU (1) RU2001122708A (pt)
TR (1) TR200102012T2 (pt)
WO (1) WO2000041678A1 (pt)
ZA (1) ZA200106499B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335460A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU6536400A (en) * 1999-08-11 2001-03-05 Alkermes Controlled Therapeutics, Inc. Method of delivering a chemotherapeutic agent to a solid tumor
WO2002003957A2 (en) * 2000-07-07 2002-01-17 Guilford Pharmaceuticals, Inc. Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
US20020045668A1 (en) * 2000-07-17 2002-04-18 Wenbin Dang Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2001296800A1 (en) * 2000-10-06 2002-04-15 Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
WO2002030472A2 (en) * 2000-10-12 2002-04-18 Guilford Pharmaceuticals, Inc. Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20030133903A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of prostate cancers and methods of making and using the same
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
AU2003202255A1 (en) * 2002-01-09 2003-07-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US8563328B2 (en) * 2004-07-26 2013-10-22 University Of Louisville Research Foundation, Inc. Fiber-optic biosensor and biosensing methods
US7871573B2 (en) * 2004-07-26 2011-01-18 University Of Louisville Research Foundation, Inc. Enhancement of sensitivity of fluorophore mediated biosensing and bioimaging
US7517914B2 (en) * 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
CN103122132B (zh) 2006-07-20 2016-03-16 奥巴斯尼茨医学公司 用于医疗器械的可生物吸收聚合物组合物
US20090169628A1 (en) * 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
CN103212115B (zh) 2006-10-20 2016-09-14 奥巴斯尼茨医学公司 可生物吸收的聚合物组合物和医疗设备
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
EP2242481A1 (en) * 2007-12-31 2010-10-27 Armark Authentication Technologies, LLC Article and method for focused delivery of therapeutic and/or diagnostic materials
US20100078848A1 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US20100291384A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
EA201490302A1 (ru) * 2011-07-19 2014-07-30 Стс. Юнм Вводимые внутрибрюшинно наноносители, высвобождающие терапевтическую нагрузку в зависимости от воспалительной среды раковых опухолей
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA597473A (en) 1960-05-03 Starck Werner Process for the manufacture of phosphorus-containing polyesters and copolymers thereof
US2891915A (en) 1954-07-02 1959-06-23 Du Pont Organophosphorus polymers
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (pt) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
WO1995017901A1 (en) 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1996022786A1 (en) 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
IL126422A (en) 1996-04-23 2004-02-19 Kinerton Ltd Biodegradable acidic polylactic polymers and methods for their preparation
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
PL335891A1 (en) 1997-03-27 2000-05-22 Baker Norton Pharma Methods of and compositions for treating ovarian carcinoma
IL132120A0 (en) 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
AU749644B2 (en) 1997-04-30 2002-06-27 Guilford Pharmaceuticals Inc. Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
AU746351B2 (en) 1997-06-18 2002-04-18 Guilford Pharmaceuticals Inc. Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
AU6283399A (en) 1998-10-02 2000-04-26 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents

Also Published As

Publication number Publication date
US20010038849A1 (en) 2001-11-08
CA2359109C (en) 2011-02-22
RU2001122708A (ru) 2004-02-20
CZ20012416A3 (cs) 2001-11-14
US6479067B2 (en) 2002-11-12
WO2000041678A1 (en) 2000-07-20
NO20013402L (no) 2001-09-11
DE69928567D1 (de) 2005-12-29
ATE310506T1 (de) 2005-12-15
US6641833B2 (en) 2003-11-04
KR20010101472A (ko) 2001-11-14
JP2002534456A (ja) 2002-10-15
CN1337878A (zh) 2002-02-27
AU779182B2 (en) 2005-01-13
HUP0202670A2 (hu) 2002-11-28
IN2001CH01053A (en) 2005-03-04
MXPA01007018A (es) 2005-07-01
HUP0202670A3 (en) 2003-02-28
TR200102012T2 (tr) 2002-01-21
MX236541B (es) 2006-05-04
EP1140028A1 (en) 2001-10-10
ZA200106499B (en) 2002-11-07
EP1140028B1 (en) 2005-11-23
DE69928567T2 (de) 2006-08-17
US20030138493A1 (en) 2003-07-24
US6350464B1 (en) 2002-02-26
IL145087A0 (en) 2002-06-30
CA2359109A1 (en) 2000-07-20
US20040071774A1 (en) 2004-04-15
AU2059100A (en) 2000-08-01
IL144087A0 (en) 2002-05-23
NO20013402D0 (no) 2001-07-09

Similar Documents

Publication Publication Date Title
BR9916881A (pt) Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
BG105851A (en) Gcsf conugates
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
BR0212169A (pt) Composição polimérica, processos para a preparação da mesma e de um derivado de poliisobuteno, e, derivado de poliisobuteno
CA2316919A1 (en) Novel macrolides
BR0010575A (pt) Composição de amaciamento de tecido, e, método de depositar um agente de amaciamento de tecido não iÈnico no tecido de uma composição de amaciamento de tecido
ES2131266T3 (es) Copolimeros de bloques lineales, procedimiento para su preparacion y composiciones adhesivas que los contienen.
ES2161615A1 (es) Composiciones de heparinas de muy bajo peso molecular.
ES8802206A1 (es) Procedimiento para la preparacion de microparticulas que permiten la liberacion prolongada de una substancia biologicameente activa.
BR0110837A (pt) Quimioterapia de combinação
AR003928A1 (es) Comprimido del liberacion controlada
AR020780A1 (es) Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo
NZ790651A (en) Anti-cd137 antigen-binding molecule for use in cancer treatment
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PT1150621E (pt) Composicao para a prevencao de adesoes cirurgicas e danificacoes de tecido utilizando polimeros fluorados
MX2007005275A (es) Composicion antiviral.
JP2004149468A (ja) 皮膚外用剤組成物
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
WO2001012632A3 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique
WO2002008231A3 (en) Biologically active macrolides, compositions, and uses thereof
PL353453A1 (en) Ascididemin derivatives and their therapeutic applications
TW371629B (en) Solubilized cosmetic composition containing alkyl modified carboxyvinyl polymer and hydroxyalkylated cyclodextrin

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]